VATE INNOVATE Corp.
$7.16▲ +1.13%
Industrials
Other
After hours
$7.16▼ -0.14%
Sep 11, 4:00 PM ET
Volume 99.3K
Avg Volume (10D) 97.0K
Key Metrics & Fundamentals
Market Cap
$97.68M
P/E Ratio
–
Div Yield
9.62%
52W Range
3.75 - 21.30
% vs 50 MA
-15.98%
% vs 200 MA
-16.77%
RSI-14
42.6
MACD Histogram
+0.0700
Beta (1Y vs SPY)
0.64
Free Cash Flow
-$35.00M
Gross Rev
$421.60M
Gross Profit
$79.50M
EBITDA
$41.90M
COGS
$342.10M
Operating Exp
$45.00M
Operating Income
$34.50M
EBIT
$34.50M
Pretax Income
$25.50M
Net Income
$10.70M
EPS (Diluted)
0.71
Price & Volume History
Loading chart…
Recent News
INNOVATE Announces Closing of the Sale of a Controlling Interest in its Broadcasting Segment to CONX
GlobeNewswire · Sep 2, 2026 12:30 PM
Could IES Holdings (IESC) Win Big While INNOVATE (VATE) Bets its Future on Debt Reduction?
Insider Monkey · Aug 29, 2026 1:19 AM
VATE Q2 Earnings Improve Y/Y as Infrastructure Revenues Surge
Zacks · Aug 18, 2026 1:53 PM
MediBeacon® Transdermal GFR System Nominated for 2026 Prix Galien USA Best Medical Technology
GlobeNewswire · Aug 18, 2026 12:00 PM
Top Midday Decliners
MT Newswires · Aug 10, 2026 7:10 PM
IES to Acquire DBM Global From Innovate for $650 Million
MT Newswires · Aug 10, 2026 12:45 PM
INNOVATE Q2 Earnings Call Highlights
MarketBeat · Aug 9, 2026 2:04 PM
Top Premarket Gainers
MT Newswires · Aug 7, 2026 11:10 AM
Innovate Corp (VATE) (Q2 2026) Earnings Call Highlights: Record Infrastructure Performance and ...
GuruFocus.com · Aug 7, 2026 5:12 AM
INNOVATE Corp. Announces Second Quarter 2026 Results
GlobeNewswire · Aug 6, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VATE's money flow as a full page
Social Sentiment
No Reddit posts found for VATE.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.